Iloprost, a synthetic analogue of prostacyclin broadly used for the treatment of SSc, was reported to significantly inhibit EndMT in human healthy dermal endothelial cells challenged with TGF-β and in SSc dermal endothelial cells [58]. This evidence concerns the gene TGFB1 and systemic sclerosis.